MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Down 4.3% – Time to Sell?

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA)’s share price dropped 4.3% during mid-day trading on Thursday . The company traded as low as $1.09 and last traded at $1.10. Approximately 69,365 shares changed hands during trading, a decline of 96% from the average daily volume of 1,921,606 shares. The stock had previously closed at $1.15.

MIRA Pharmaceuticals Price Performance

The firm has a market capitalization of $18.22 million, a price-to-earnings ratio of -1.96 and a beta of 2.31. The business’s 50 day moving average price is $1.12 and its 200-day moving average price is $1.23.

Hedge Funds Weigh In On MIRA Pharmaceuticals

A number of large investors have recently modified their holdings of MIRA. International Assets Investment Management LLC purchased a new stake in shares of MIRA Pharmaceuticals in the fourth quarter valued at approximately $29,000. Virtu Financial LLC acquired a new stake in MIRA Pharmaceuticals in the fourth quarter valued at $72,000. Renaissance Technologies LLC acquired a new stake in MIRA Pharmaceuticals in the fourth quarter valued at $52,000. Northern Trust Corp boosted its position in shares of MIRA Pharmaceuticals by 50.9% during the 4th quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock worth $35,000 after purchasing an additional 10,238 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of MIRA Pharmaceuticals during the 4th quarter worth $112,000. 35.16% of the stock is owned by hedge funds and other institutional investors.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.